Similarly, MR analysis based on the Prostate Cancer Association Group to Investigate Cancer-Associated Alterations (Figure 6, panel B) and the FinnGen cohort (Figure 6, panel C) provided genetic evidence that the use of agents acting on the renin-angiotensin system decreased the odds of prostate cancer. This evidence concerns the gene REN and Familial prostate cancer.